Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 5, 2014, Pages 553-561

  Wan, Ping ^a   Zhang, Jianjun ^a   Long, Xidai ^a   Li, Qigen ^a   Xu, Ning ^a   Zhang, Ming ^a   Chen, Xiaosong ^a   Han, Longzhi ^a   Xia, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

biomarker; CA19 9; hepatocellular carcinoma; liver cancer; liver transplantation; survival; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; AFP PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GAMMA KNIFE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; BLOOD; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; ALPHA-FETOPROTEINS; CA-19-9 ANTIGEN; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898432307     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000070     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61:69-90.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699.
3. Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011; 53:1570-1579.
4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394-1403.
5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10:35-43.
6. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25:310-312.
7. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13:1637-1644.
8. Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, et al. Liver transplantation outcomes in 1078 hepatocellular carcinoma patients: a multi- center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135:1403-1412.
9. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85:1726-1732.
10. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
11. Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-5327.
12. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48 900 necropsies. Cancer 1954; 7:462-503.
13. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, et al. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl 2013; 19:1020-1029.
14. Todo S, Furukawa H. Japanese study group on organ transplantation: living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240:459-461.
15. Gao T, Xia Q, Qiu de K, Feng YY, Chi JC, Wang SY, et al. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. J Dig Dis 2013; 14:552-558.
16. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34:570-575.
17. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36:S84-S92.
18. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43:434-441.
19. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of patients. Hepatology 1998; 28:751-755.
20. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
21. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108:865-869.
22. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 2013; 11:898-907.
23. Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol 2005; 124:355-360.
24. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:204-207.
25. Chen YL, Chen CH, Hu RH, Ho MC, Jeng YM. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection. ScientificWorldJournal 2013; 2013: 380797.
26. Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006; 41:893-900.
27. Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008; 23:766-770.
28. Zhu HF, Li J, Huang L, Yan YQ. Intrahepatic cholangiocarcinoma: a clinicopathologic study of 37 resected cases. Hepatogastroenterology 2013; 60:263-267.
29. He CZ, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol 2013; 13:87.
30. Llovet JM, Pen?a CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2290-2300.
31. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gammacarboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91:561-569.
32. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007; 102:2196-2205.